Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503497 | 1.00 | KDM4E (0.54) | KDM4EPKMGPR119L3MBTL1TP53 | |
| SCHEMBL6522277 | 0.91 | KDM4E (0.54) | KDM4EPKMGPR119L3MBTL1TP53 | |
| SCHEMBL15208916 | 0.87 | PRMT5 (0.48) | KDM4EPKMGPR119L3MBTL1TP53 | |
| SCHEMBL31314345 | 0.86 | KDM4E (0.49) | KDM4EPKMGPR119L3MBTL1TP53 | |
| SCHEMBL31314168 | 0.86 | KDM4E (0.49) | KDM4EPKMGPR119L3MBTL1TP53 | |
| SCHEMBL29890980 | 0.84 | ACHE (0.64) | KDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL8825578 | 0.84 | ACHE (0.64) | KDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL23884184 | 0.84 | ACHE (0.51) | KDM4EPKMGPR119L3MBTL1 | |
| SCHEMBL6953531 | 0.83 | ACHE (0.55) | KDM4EPKMGPR119 | |
| SCHEMBL31271469 | 0.83 | CHRM2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| EP-1708755-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005070468-A2 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | KDM4E 3476/4885PKM 3834/4885GPR119 103/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | KDM4E 3762/4885PKM 744/4885GPR119 1874/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | KDM4E 4510/4885PKM 2898/4885GPR119 2097/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | KDM4E 3762/4885PKM 744/4885GPR119 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.